AUTHOR INFORMATION

Section 1 of 11

Authored by Joseph U Becker, MD, Consulting Staff, Department of Surgery/Emergency Medicine, Yale University School of Public Health

Coauthored by Charles R Wira, MD, Assistant Professor, Department of Surgery, Section of Emergency Medicine, Yale School of Medicine; Jeffrey L Arnold, MD, FACEP, Chairman, Department of Emergency Medicine, Santa Clara Valley Medical Center

Edited by Richard S Krause, MD, Clinical Assistant Professor, Residency Program Director, Department of Emergency Medicine, State University of New York at Buffalo School of Medicine; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; J Stephen Huff, MD, Associate Professor of Emergency Medicine and Neurology, Department of Emergency Medicine, University of Virginia Health System; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Charles V Pollack, Jr, MD, MA, FACEP, Professor, Department of Emergency Medicine, University of Pennsylvania College of Medicine; Chairman, Department of Emergency Medicine, Pennsylvania Hospital

Author's Email:	Joseph U Becker, MD
Editor's Email:	Richard S Krause, MD

eMedicine Journal, September 5 2006, VOLUME 7, Number 9

INTRODUCTION

Section 2 of 11

Background: Stroke is characterized by the sudden loss of blood circulation to an area of the brain, resulting in a corresponding loss of neurologic function. Also called cerebrovascular accident or stroke syndrome, stroke is a nonspecific term encompassing a heterogeneous group of pathophysiologic causes, including thrombosis, embolism, and hemorrhage.

Strokes currently are broadly classified as either hemorrhagic or ischemic. Acute ischemic stroke refers to strokes caused by thrombosis or embolism and accounts for 85% of all strokes.

Emergency physicians play a central role in the initial evaluation and management of patients with acute strokes. In 1992, a National Institute of Neurologic Disorders and Stroke (NINDS) t-PA Pilot Trial succeeded at enrolling patients within 90 minutes, which led to the NINDS requirement that investigators from emergency medicine be involved in the larger randomized trial. The NINDS recombinant tissue-type plasminogen activator (rt-PA) stroke study group first reported that the early administration of rt-PA benefited carefully selected patients with acute ischemic stroke.

The trial had a positive outcome leading to the current standard of care of t-PA administration within a 3-hour window. The collaboration between emergency physicians and neurologists was visionary and enabled the early enrollment of patients, which was an integral component of the positive results. Encouraged by this breakthrough study and the subsequent approval of t-PA for use in acute ischemic stroke by the US Food and Drug Administration, many medical professionals now consider acute ischemic stroke to be a medical emergency, which when detected and treated early can have few, if any, permanent sequelae.

Since emergency physicians play a central role in the initial evaluation and treatment of patients with acute ischemic stroke, their understanding of its pathophysiology, clinical presentation, and ED evaluation is essential. The emergency physician also must be completely familiar with the entire therapeutic armamentarium currently available to treat acute ischemic stroke, which includes supportive care, treatment of neurologic complications, antiplatelet therapy, glycemic control, blood pressure control, prevention of hyperthermia, and thrombolytic therapy.

In recent years, significant advances have also been made in stroke prevention, supportive care, and rehabilitation. With emerging evidence that the brief counsel of emergency physicians may impact primary and secondary prevention of disease processes, the emergency medicine specialty is also challenged to be vigilant in utilizing "teachable moments" or "brief negotiated interviews" to impact patient education, awareness, and compliance with established preventative treatments. Overall, when the direct costs (care and treatment) and the indirect costs (lost productivity) of strokes are considered together, strokes cost US society $43.3 billion per year.

Pathophysiology: On the macroscopic level, ischemic strokes most often are caused by extracranial embolism or intracranial thrombosis, but they may also be caused by decreases in cerebral blood flow. On the cellular level, any process that disrupts blood flow to a portion of the brain unleashes an ischemic cascade, leading to the death of neurons and cerebral infarction. Understanding this chain of events is important for understanding current therapeutic approaches.

Embolism

Emboli may arise from the heart, the extracranial arteries or, rarely, the right-sided circulation (paradoxical emboli). The sources of cardiogenic emboli include valvular thrombi (eg, in mitral stenosis, endocarditis, prosthetic valves), mural thrombi (eg, in myocardial infarction [MI], atrial fibrillation, dilated cardiomyopathy, severe congestive heart failure [CHF]), and atrial myxomas. MI is associated with a 2-3% incidence of embolic stroke, of which 85% occur in the first month after MI.

Thrombosis

Thrombotic strokes can be divided into large vessel, including the carotid artery system, or small vessel comprising the intracerebral arteries, including the branches of the Circle of Willis and the posterior circulation. The most common sites of thrombotic occlusion are cerebral artery branch points, especially in the distribution of the internal carotid artery. Arterial stenosis (ie, turbulent blood flow), atherosclerosis (ie, ulcerated plaques), and platelet adherence cause the formation of blood clots that either embolize or occlude the artery. Less common causes of thrombosis include polycythemia, sickle cell anemia, protein C deficiency, fibromuscular dysplasia of the cerebral arteries, and prolonged vasoconstriction from migraine headache disorders. Any process that causes dissection of the cerebral arteries also can cause thrombotic stroke (eg, trauma, thoracic aortic dissection, arteritis). Occasionally, hypoperfusion distal to a stenotic or occluded artery or hypoperfusion of a vulnerable watershed region between 2 cerebral arterial territories can cause ischemic stroke.

Flow disturbances

Stroke symptoms can result from inadequate cerebral blood flow due to decreased blood pressure or due to hematologic hyperviscosity due to sickle cell disease or other hematologic illnesses such as multiple myeloma and polycythemia vera. In these instances, cerebral injury may occur in the presence of damage to other organ systems.

Ischemic cascade

Within seconds to minutes of the loss of perfusion to a portion of the brain, an ischemic cascade is unleashed that, if left unchecked, causes a central area of irreversible infarction surrounded by an area of potentially reversible ischemic penumbra.

On the cellular level, the ischemic neuron becomes depolarized as ATP is depleted and membrane ion-transport systems fail. The resulting influx of calcium leads to the release of a number of neurotransmitters, including large quantities of glutamate, which, in turn, activates N-methyl-D-aspartate (NMDA) and other excitatory receptors on other neurons. These neurons then become depolarized, causing further calcium influx, further glutamate release, and local amplification of the initial ischemic insult. This massive calcium influx also activates various degradative enzymes, leading to the destruction of the cell membrane and other essential neuronal structures.

Free radicals, arachidonic acid, and nitric oxide are generated by this process, which leads to further neuronal damage. Within hours to days after a stroke, specific genes are activated, leading to the formation of cytokines and other factors that in turn cause further inflammation and microcirculatory compromise. Ultimately, the ischemic penumbra is consumed by these progressive insults, coalescing with the infracted core, often within hours of the onset of the stroke.

The central goal of therapy in acute ischemic stroke is to preserve the area of oligemia in the ischemic penumbra. The area of oligemia can be preserved by limiting the severity of ischemic injury (ie, neuronal protection) or by reducing the duration of ischemia (ie, restoring blood flow to the compromised area).

The ischemic cascade offers many points at which such interventions could be attempted. Multiple strategies for blocking this cascade are currently under investigation. The timing of restoring cerebral blood flow appears to be a critical factor. Time also may prove to be a key factor in neuronal protection. Although still being studied, neuroprotective agents, which block the earliest stages of the ischemic cascade (eg, glutamate receptor antagonists, calcium channel blockers), are expected to be effective only in the proximal phases of presentation.

Frequency:

• In the US: Incidence for first-time strokes is more than 400,000 per year. At current trends, this number is projected to jump to one million per year by the year 2050.

• Internationally: Global incidence of stroke is unknown.

Mortality/Morbidity: Stroke is the third leading cause of death and the leading cause of disability in the United States.

• Cerebrovascular disease was the second leading cause of death worldwide in 1990, killing over 4.3 million people.

• Cerebrovascular disease was also the fifth leading cause of lost productivity, as measured by disability-adjusted life years (DALYs). DALYs include years of productivity lost to either death or varying degrees of disability. In 1990, cerebrovascular disease caused 38.5 million DALYs throughout the world.

Sex: Men are at higher risk for stroke than women. Additionally, women seem to respond better than men to interventions such as rt-PA.

Age: Although stroke often is considered a disease of elderly persons, 25% of strokes occur in persons younger than 65 years.

CLINICAL

Section 3 of 11

History:

• Stroke should be considered in any patient presenting with an acute neurologic deficit (focal or global) or altered level of consciousness.

• No historical feature distinguishes ischemic from hemorrhagic stroke, although nausea, vomiting, headache, and change in level of consciousness are more common in hemorrhagic strokes.

• Common symptoms of stroke include abrupt onset of hemiparesis, monoparesis, or quadriparesis; monocular or binocular visual loss; visual field deficits; diplopia; dysarthria; ataxia; vertigo; aphasia; or sudden decrease in the level of consciousness.

• Although such symptoms can occur alone, they are more likely to occur in combination.

• Establishing the time of onset of these symptoms is of paramount importance when considering patients for possible thrombolytic therapy. An essential question is, “When was the patient last seen normal?” It is advisable for emergency physicians to rapidly enlist the assistance of family members or relatives to establish time of onset and to identify other pertinent components of the patient’s history of presentation. The median time from symptom onset to ED presentation ranges from 4-24 hours in the United States.

• Multiple factors contribute to delays in seeking care for symptoms of stroke.

• Many strokes occur while patients are sleeping (also known as "wake-up" strokes) and are not discovered until the patient wakes.

• Strokes leave some patients too incapacitated to call for help.

• Occasionally, strokes go unrecognized by patients or their caregivers.

• Stroke mimics commonly confound the clinical diagnosis of stroke. One study reported that 19% of patients diagnosed with acute ischemic stroke by neurologists before cranial CT scanning actually had noncerebrovascular causes for their symptoms. The most frequent stroke mimics include seizures (17%); systemic infections (17%); brain tumors (15%); toxic-metabolic causes, such as hyponatremia (13%); and positional vertigo (6%). Miscellaneous disorders mimicking stroke include syncope, trauma, subdural hematoma, herpes encephalitis, transient global amnesia, dementia, demyelinating disease, myasthenia gravis, parkinsonism, hypertensive encephalopathy, and conversion disorders. A critical masquerading metabolic derangement not to be missed by providers is hypoglycemia.

Physical:

• The goals of the physical examination include detecting extracranial causes of stroke symptoms and distinguishing stroke from stroke mimics.

• The physical examination always includes a careful head and neck examination for signs of trauma, infection, and meningeal irritation.

• A careful search for the cardiovascular causes of stroke requires examination of the ocular fundi (retinopathy, emboli, hemorrhage), heart (irregularities, murmurs, gallops), and peripheral vasculature (palpation of carotid, radial, and femoral pulses, auscultation for carotid bruits).

• Patients with a decreased level of consciousness should be assessed to ensure that they are able to protect their airway.

• Neurologic examination

• With the availability of thrombolytic therapy for acute ischemic stroke in selected patients, the emergency physician must be able to perform a brief but accurate neurologic examination on patients with suspected stroke syndromes.

• The goals of the neurologic examination include (1) confirming the presence of a stroke syndrome (to be defined further by cranial CT scanning), (2) distinguishing stroke from stroke mimics, and (3) establishing a neurologic baseline should the patient's condition improve or deteriorate.

• Essential components of the neurologic exam include evaluation of mental status and the level of consciousness, cranial nerves, motor function, sensory function, cerebellar function, gait, and deep tendon reflexes.

• The skull and spine also should be examined, and signs of meningismus should be sought.

• Central facial weakness from a stroke should be differentiated from the peripheral weakness of Bell palsy. With peripheral lesions (Bell palsy), the patient is unable to lift the eyebrows or wrinkle the forehead.

• The 4 major neuroanatomic stroke syndromes are caused by disruption of their respective cerebrovascular distributions. Correlating the patient's neurologic deficits with the expected sites of arterial compromise may assist the emergency physician in confirming the diagnosis of stroke and interpreting the subsequent cranial CT scan.

• Middle cerebral artery (MCA) occlusions commonly produce contralateral hemiparesis, contralateral hypesthesia, ipsilateral hemianopsia (blindness in one half of the visual field), and gaze preference toward the side of the lesion. Agnosia is common, and receptive or expressive aphasia may result if the lesion occurs in the dominant hemisphere. Neglect, inattention, and extinction of double simultaneous stimulation may occur in nondominant hemisphere lesions. Since the MCA supplies the upper extremity motor strip, weakness of the arm and face is usually worse than that of the lower limb.

• Anterior cerebral artery occlusions primarily affect frontal lobe function and can result in dis-inhibition and speech perseveration, producing primitive reflexes (eg, grasping, sucking reflexes), altered mental status, impaired judgment, contralateral weakness (greater in legs than arms), contralateral cortical sensory deficits gait apraxia, and urinary incontinence.

• Posterior cerebral artery occlusions affect vision and thought, producing contralateral homonymous hemianopsia, cortical blindness, visual agnosia, altered mental status, and impaired memory.

• Vertebrobasilar artery occlusions are notoriously difficult to detect because they cause a wide variety of cranial nerve, cerebellar, and brainstem deficits. These include vertigo, nystagmus, diplopia, visual field deficits, dysphagia, dysarthria, facial hypesthesia, syncope, and ataxia. A hallmark of posterior circulation strokes is that there are crossed findings: ipsilateral cranial nerve deficits and contralateral motor deficits. This is contrasted to anterior strokes, which produce findings on one side of the body only.

• Lastly, lacunar strokes are strokes resulting from occlusion of the small, perforating arteries of the deep subcortical areas of the brain. The resulting infarcts are generally from 2-20 mm in diameter. The most common lacunar syndromes include pure motor, pure sensory, and ataxic hemiparetic strokes. Lacunar infarcts are often associated with partial or full occlusion of the parent feeding artery. Lacunar strokes account for 13-20% of all cerebral infarctions. Lacunar infarcts commonly occur in patients with small vessel disease, such as diabetes and hypertension. By virtue of their small size and well-defined subcortical location, lacunar infarcts do not lead to impairments in cognition, memory, speech, or level of consciousness

• Stroke scales: The National Institutes of Health Stroke Scale (NIHSS) is a rapid and reproducible tool for quantifying neurologic deficits in stroke patients and is useful for following the patient's early course. It is advisable for emergency physicians to use this scale because it provides a means of quantitatively following a patient’s course (ie, rapidly improving symptoms, or, escalation of symptoms secondary to either a bleed or cerebral edema). The NIHSS is a 42-point scale with minor strokes usually being considered to have a score less than 5. A NIHSS score greater than 10 correlates with an 80% likelihood of visual flow deficits on angiography. Physician discretion must be also be used in assessing the magnitude of the clinical deficit; for instance, if a patient’s only deficit is being mute, then the NIHSS score will be 3. Additionally, the scale does not measure some deficits associated with posterior circulation strokes (ie, vertigo, ataxia). The scale is available online at National Institutes of Health Stroke Scale.

Causes:

• Risk factors

• Briefly assessing the risk factors for stroke may provide clues as to its cause and reinforce the clinical gestalt the emergency physician may have in uncertain situations. Risk factors for ischemic stroke include advanced age (the risk doubles every decade), hypertension, smoking, heart disease (coronary artery disease, left ventricular hypertrophy, chronic atrial fibrillation), and hypercholesterolemia. Hyperhomocysteinemia has also been identified as an independent risk factor for all etiologic forms of stroke.

• Diseases associated with increased blood viscosity and the use of oral contraceptives place patients at higher risk for ischemic stroke.

• Previous cerebrovascular disease is a risk factor for ischemic stroke.

• Transient ischemic attack

• Transient ischemic attack has come to be known as a neurologic deficit that resolves within 24 hours. Roughly 80% resolve within 60 minutes. Tissue-based definitions are being proposed with magnetic resonance imaging.

• Transient ischemic attacks (TIAs) can result from any of the aforementioned mechanisms of stroke and precede nearly 30% of ischemic strokes. If left untreated, one third of TIAs lead to ischemic stroke: 20% within the first month and 50% within the first year.

DIFFERENTIALS

Section 4 of 11

Guillain-Barré Syndrome
Hyperosmolar Hyperglycemic Nonketotic Coma
Status Epilepticus

WORKUP

Section 5 of 11

Lab Studies:

• CBC, basic chemistry panel, coagulation studies, and cardiac biomarkers should be obtained in most patients.

• CBC serves as a baseline study and may reveal a cause for the stroke (eg, polycythemia, thrombocytosis, thrombocytopenia, leukemia) or provide evidence of concurrent illness (eg, anemia).

• Chemistry panel serves as a baseline study and may reveal a stroke mimic (eg, hypoglycemia, hyponatremia) or provide evidence of concurrent illness (eg, diabetes, renal insufficiency).

• Coagulation studies may reveal a coagulopathy and are useful when thrombolytics or anticoagulants are to be used.

• Cardiac biomarkers are important because of the association of cerebral vascular disease and coronary artery disease. Additionally, several studies have indicated a link between elevations of cardiac enzyme levels and poor outcomes in ischemic stroke.

• Toxicology screens may be useful in selected patients.

Imaging Studies:

• Noncontrast head CT scan

• Emergent noncontrast head CT scanning is mandatory for rapidly distinguishing ischemic from hemorrhagic infarction and for defining the anatomic distribution of stroke. CT perfusion is a novel modality potentially useful in identifying early areas of ischemia. Noncontrast head CT in combination with CT-angiography and CT perfusion imaging has been shown to have increased sensitivity when compared with any of the individual imaging modalities alone.

• Head CT scan is a fundamental branch point in the evaluation of stroke, since patients with acute ischemic stroke may be triaged to receive thrombolytic therapy, while patients with hemorrhagic stroke are taken down a completely different diagnostic and therapeutic pathway.

• CT scans also may rule out other life-threatening processes, such as hematomas, neoplasms, and abscesses.

• The changes in CT scan over the time course of acute cerebral infarction must be understood. The sensitivity of standard noncontrast head CT increases 24 hours post ischemic event. After 6-12 hours, sufficient edema is recruited into the stroke area to produce a regional hypodensity on CT scan. A large hypodense area present on CT scan within the first 3 hours of symptom onset should prompt careful requestioning regarding the time of stroke symptom onset. The presence of CT evidence of infarction early in presentation has also been associated with poor outcome.

• Other radiologic clues to acute ischemic infarction include the insular ribbon sign, the hyperdense MCA sign, obscuration of the lentiform nucleus, sulcal asymmetry, and loss of gray-white matter differentiation.

• Unfortunately, as many as 5% of patients with subarachnoid hemorrhages also have normal CT scans, making lumbar puncture imperative when subarachnoid hemorrhage is suspected. CT scans also may fail to demonstrate some parenchymal hemorrhages smaller than 1 cm.

• Further imaging

• Carotid duplex scanning is reserved for patients with acute ischemic stroke in whom carotid artery stenosis or occlusion is suspected.

• Transcranial Doppler ultrasound is useful for evaluating more proximal vascular anatomy, including the MCA, intracranial carotid artery, and vertebrobasilar artery.

• Echocardiography is obtained in all patients with acute ischemic stroke in whom cardiogenic embolism is suspected. Transesophageal echocardiography is useful for detecting thoracic aortic dissection and more accurate for identification of thrombi in the left atrial appendage from atrial fibrillation. A certain proportion of patients with strokes may have underlying systolic dysfunction, diastolic dysfunction, or concentric hypertrophy. Echocardiography is also a modality to identify the presence of a patent foramen ovale.

• Magnetic resonance imaging

• MRI, especially diffusion-weighted MRI (DWI-MRI) has been shown to have higher sensitivity than standard noncontrast head CT in demonstrating infarcts early after symptom onset. Diffusion and perfusion MRIs correlate respectively with the core area of infarct and surrounding area of oligemia (ischemic penumbra).

• Disadvantages include its high cost, lack of ready availability at most centers, and insensitivity for detecting early hemorrhages.

Other Tests:

• Electrocardiogram

• ECG should be obtained on all patients with acute stroke because as many as 60% of all cardiogenic emboli are associated with atrial fibrillation or acute MI.

• Some have also recommended continuous cardiac monitoring for all patients, since 4% of patients have a life-threatening arrhythmia during the course of their illness and 3% have concurrent MI. Acute ischemic stroke has been associated with acute cardiac dysfunction and arrhythmia, which are then associated with worse functional outcome and morbidity at 3 months.

Procedures:

• Angiography

• Angiography is useful for patients with acute ischemic stroke in whom characterization of the cerebrovascular anatomy might lead to change in medical or surgical management, such as patients with subtle occlusive diseases (eg, fibromuscular dysplasia, vasculitis) or arterial dissection.

• Angiography continues to play an important role in the preoperative evaluation of carotid artery disease.

TREATMENT

Section 6 of 11

Prehospital Care: Recognition that a stroke may have occurred and rapid transport to the appropriate receiving facility are necessary after addressing ABCs. Stroke should be a priority dispatch with prompt EMS response.

Emergency Department Care:

• Airway and breathing
  • Patients presenting with Glasgow Coma Scale scores less than or equal to 8, rapidly decreasing Glasgow Coma Scale scores, or inadequate airway protection reflexes require emergent airway control via rapid sequence intubation.

• When increased intracranial pressure is suspected, rapid sequence induction might ideally include pretreatment with lidocaine (1.5 mg/kg IV), fentanyl (3 mcg/kg IV), and a subparalytic defasiculating dose of a nondepolarizing neuromuscular blocker (eg, pancuronium 0.01 mg/kg IV) at least 2 minutes before paralysis with succinylcholine (2 mg/kg IV) and oral endotracheal intubation.

• The goal of mechanical ventilation is hyperventilation, which decreases intracranial pressure by decreasing cerebral blood flow. The recommended endpoint of hyperventilation is an arterial pCO₂ of 32-36 mm Hg. Supplemental oxygen requirements should be guided by pulse oximetry. Patients should only receive supplemental oxygen if their pulse oximetry or arterial blood gas reveals that they are hypoxic.

• Circulation: Patients require intravenous access and cardiac monitoring in the ED.

• Blood glucose control: Recent data suggest that severe hyperglycemia is independently associated with poor outcome and reduced reperfusion in thrombolysis. Additionally, normoglycemic patients should not be given excessive glucose-containing intravenous fluids, as glucose may exacerbate ischemic cerebral injury.

• Head positioning: Studies have shown that cerebral perfusion pressure is maximized when patients are maintained in a supine position. However, lying flat may serve to increase ICP and thus is not recommended in cases of subarachnoid or other intracranial hemorrhage. Because prolonged immobilization may lead to its own complications including deep venous thrombosis, pressure ulcer aspiration, and pneumonia patients should not be kept flat for longer than 24 hours.

• Blood pressure control: In poor flow states as occurs with thrombotic and embolic ischemic strokes and as well in increased ICP due to cerebral edema, the cerebral vasculature is without vasoregulatory capability and thus relies directly on MAP and cardiac output for maintenance of cerebral blood flow. Therefore, aggressive efforts to lower blood pressure may decrease perfusion pressure and may prolong or worsen ischemia. However, hypertension in the setting of hemorrhagic stroke should always be managed. The management of blood pressure in patients with acute ischemic stroke is divided into those who are candidates for thrombolytics and those who are not.

• Non–t-PA candidates
  • For patients who are not rt-PA candidates and whose systolic blood pressure is less than 200 mm Hg and whose diastolic blood pressure is less than 120 mm Hg in the absence of evidence of end-organ involvement (ie, pulmonary edema, aortic dissection, hypertensive encephalopathy), blood pressure should be monitored and stroke symptoms and complications should be treated (increased ICP, seizures).

  • For patients with elevated diastolic blood pressures between 120 and 140 mm Hg labetalol (10-20 mg IV for 1-2 min) should be the initial drug of choice, unless a contraindication to its use exists. Dosing may be repeated or doubled every 10 minutes to a maximum dose of 300 mg. Alternatively, nicardipine (5 mg/h IV initial infusion) titrated to effect via increasing 2.5 mg/h every 5 minutes to a maximum dose of 15 mg/h may be used for blood pressure control.

  • Lastly, nitroprusside at 0.5 mcg/kg/min IV infusion may be used in the setting of continuous blood pressure monitoring. The goal of intervention being a reduction of 10-15% of blood pressure.

• t-PA eligible candidates
  • For patients who will be receiving rt-PA, systolic blood pressure greater than 185 mm Hg and diastolic blood pressure greater than 110 mm Hg require intervention. The initial drug of choice is labetalol (10-20 mg IV for 1-2 min). One to two inches of nitropaste may also be used. For diastolic blood pressures greater than 140 mm Hg, sodium nitroprusside 0.5 mcg/kg/min initial IV dose titrated to effect.

  • For systolic blood pressure greater than 185 mm Hg or diastolic blood pressure between 120 and 140 mm Hg, labetalol or nicardipine, at the above dosing regimens may be used. Or, a labetalol drip at 2-8 mg/min may be commenced. Sodium nitroprusside may also be used.

  • Monitoring of blood pressure is crucial, and, for the first 2 hours, blood pressure should be checked every 15 minutes, then every 30 minutes for 6 hours, and finally every hour for 16 hours.

• Use of sublingual nifedipine to lower blood pressure in the ED is discouraged since extreme hypotension may result. Trials of nimodipine, initially thought to be beneficial given its vasodilatory effect as a calcium channel blocker, have additionally failed to demonstrate any beneficial outcome in comparison to placebo.

• Given the need to maintain adequate cerebral blood flow, severe hypotension should be managed in standard fashion with aggressive fluid resuscitation and if necessary vasopressor support.

• Fever control: Antipyretics are indicated for febrile stroke patients, since hyperthermia accelerates ischemic neuronal injury. Substantial experimental evidence suggests that mild brain hypothermia is neuroprotective. The use of induced hypothermia is currently being evaluated in phase I clinical trials.

• Cerebral edema control: Cerebral edema occurs in up to 15% of patients with ischemic stroke, reaching maximum severity 72-96 hours after the onset of stroke. Hyperventilation and mannitol are used routinely to decrease intracranial pressure quickly and temporarily. No evidence exists supporting the use of corticosteroids to decrease cerebral edema in acute ischemic stroke. Prompt neurosurgical assistance should be sought when indicated.

• Seizure control: Seizures occur in 5-7% of patients within the first 24 hours after stroke. Although seizure prophylaxis is not indicated, prevention of subsequent seizures with standard antiepileptic therapy is recommended.

• Acute decompensation or escalation: In the case of the rapidly decompensating patient or the patient with deteriorating neurologic status reassessment of ABCs as well as hemodynamics and reimaging are indicated. Many patients who develop hemorrhagic transformation or progressive cerebral edema will demonstrate acute clinical decline. Rarely, a patient may have escalation of symptoms secondary to increased size of the ischemic penumbra. Some advocate resetting the time window to zero in this circumstance and encourage consideration of reperfusion strategies.

MEDICATION

Section 7 of 11

Medications for the management of ischemic stroke can be distributed into the following categories (1) reperfusion, (2) antiplatelet, (3) anticoagulation, and (4) neuroprotective.

Although heparin prevents recurrent cardioembolic strokes and may help inhibit ongoing cerebrovascular thrombosis, current guidelines do not recommend anticoagulation for any subsets of patients with stroke because of insufficient data. Both randomized prospective trials evaluating t-PA for acute ischemic stroke (ECASS and NINDS) excluded patients who were receiving anticoagulants. Heparin is known to prolong the lytic state caused by t-PA. Immobilized stroke patients who are not receiving anticoagulants, such as IV heparin or an oral anticoagulant, may benefit from low-dose subcutaneous unfractionated or low molecular weight heparin, which reduces the risk of deep vein thrombosis.

The use of low molecular weight heparin as treatment for acute ischemic stroke has not yet been studied adequately. However, multiple past studies have failed to show any beneficial effect of anticoagulation in acute ischemic stroke. Although trials of anticoagulants in the treatment of acute ischemic stroke are ongoing no current data exist to support their use in acute ischemic stroke.

Experimental treatments

Neuroprotective agents

Despite very promising results in several animal studies as of yet no single neuroprotective agent in ischemic stroke is supported by randomized placebo controlled human studies. Nevertheless, substantial research is underway evaluating their use for this indication. Since the ischemic cascade is a dynamic process, the efficacy of interventions to protect the ischemic penumbra also may prove to be time dependent.

Theoretically, calcium channel blockers (eg, nimodipine) should have the narrowest window of therapeutic opportunity, since calcium influx is one of the earliest events in the ischemic cascade. A recent study suggests that lubeluzole (an inhibitor of glutamate release) may benefit patients with acute ischemic stroke if given within 6 hours. Aptiganel (noncompetitive inhibitor of the NMDA receptor) also appears promising when given early in the course of ischemia. The IMAGES study again recently failed to determine a benefit for intravenous magnesium in stroke. Further research is underway utilizing magnesium earlier in the symptom course.

Neuroprotectants affecting later events in the ischemic cascade include free-radical scavengers (tirilazad, citicoline, cerovive,) and neuronal membrane stabilizers [citicoline]). Cerovive is currently being evaluated in a large placebo controlled randomized study. Monoclonal antibodies against leukocyte adhesion molecules also are being evaluated as late neuroprotectants (enlimomab). No set classification system yet exists for the many neuroprotectants being investigated, since many agents appear to have more than one mechanism of action.

Surgical and endovascular interventions

Many surgical and endovascular techniques have been studied in the treatment of acute ischemic stroke. Carotid endarterectomy has been used in the acute management of internal carotid artery occlusions with some success (Gay, Huber, guidelines). Other interventions have included laser, intra-arterial suction, snares, angioplasty, as well as clot retrieval devices (guidelines). The MERCI 1 pilot trial studied the safety and efficacy of the Merci Retrieval System, an endovascular embolectomy system for use in ischemic stroke. Inclusion criteria included NIHSS greater than 10, treatment commencement within 8 hours of symptom onset, and contraindication to IV thrombolytics. Successful recanalization occurred in 12 of 28 patients. Twelve asymptomatic bleeds and only one procedure-related complication occurred. Among patients who had successful recanalization, there was a 50% rate of significant recovery, while, in those with no recanalization, none had significant recovery. No cases of downstream embolic events occurred as a result of the procedure.

In a second MERCI study, the same intervention was attempted in 151 patients. All study patients had been excluded from intravenous thrombolytic therapy for various reasons. Recanalization was achieved in 48% of those in which the device was deployed. Clot was successfully retrieved from all major cerebral arteries; however, the recanalization rate for the middle cerebral artery (MCA) was lowest. While the rate of asymptomatic intracerebral bleed was higher than placebo, it was lower than that of the NINDS rt-PA study (5% vs 6%). However, an overall complication rate of 7.1% was found to be comparable to the complication rates for systemic thrombolytic therapy.

While these studies suggest a treatment effect, as of yet, there has been little placebo controlled comparison. Thus, further research is required to delineate the role of endovascular embolectomy in the management of acute ischemic stroke. However, based on these results, the FDA has cleared the use of the MERCI device in patients who are either ineligible or who have failed intravenous thrombolytics.

Induced hypothermia

Hypothermia is another treatment strategy that has received recent consideration. Hypothermia is fast becoming standard of care for the resuscitation of out-of-hospital cardiac arrest. Although no major clinical studies have demonstrated a role for hypothermia in the early treatment of ischemic stroke, it is advisable to prevent hyperthermia for the first several days after acute ischemic stroke because fever has been independently associated with poor outcomes and as well failure of rt-PA thrombolysis.

Reperfusion agents (thrombolytics)

Thrombolytics restore cerebral blood flow in acute ischemic stroke, leading to improvement or resolution of neurologic deficits. Unfortunately, thrombolytics can also cause symptomatic intracranial hemorrhage, defined as radiographic evidence of hemorrhage combined with escalation of NIHSS by 4 or more points.

Major clinical trials evaluating the use of intravenous thrombolysis have included the MASK-E, MASK-I, ASK, ECASS I and II, NINDS trial, and ATLANTIS A and B. While both streptokinase and rt-PA have been shown to benefit patients with acute MI, only alteplase (rt-PA) has been shown to benefit selected patients with acute ischemic stroke. Among the rt-PA trials, ECASS I and II and ATLANTIS A and B enrolled patients up to 6 hours after symptom onset, while the NINDS rt-PA trial treated patients within a 3-hour window. Current practice guidelines originate from the NINDS data, and meta-analyses of the above listed clinical trials in the first 3 hours of presentation.

NINDS t-PA trial study group in 1995 reported that recombinant t-PA reduced disability in patients with acute ischemic stroke. NINDS enrolled 624 patients in 39 centers during the period 1991-1994. To be enrolled, patients must have had onset of stroke symptoms within 3 hours of presentation; only patients with no evidence of hemorrhage by cranial CT scan were eligible. Excluded patients were those who had rapidly improving or minor symptoms, significant pretreatment hypertension (BP >185/110 or BP requiring aggressive therapy), symptoms suggestive of subarachnoid hemorrhage, previous history of intracranial hemorrhage, recent stroke or head injury (within 3 mo), or recent major surgery (within 14 d). Also excluded were patients who had received heparin or other anticoagulants within the past 48 h, had elevated prothrombin time (PT) or activated partial thromboplastin time (aPTT); or were thrombocytopenic (platelet count <100 X 10⁹/L), hypoglycemic (glucose <50 mg/dL), or hyperglycemic (glucose >400 mg/dL).
Current guidelines for the use of rt-PA (listed below) are derived from this study.

Patients in the rt-PA group were given 0.9 mg/kg total dose of rt-PA: 10% as a bolus and 90% over 60 minutes. The maximal dose was 90 mg. All patients were admitted to an ICU, and antiplatelet and anticoagulation therapies were withheld for the first 24 hours after treatment.

NINDS reported a statistically significant increase in full recovery in patients given t-PA (39% vs 26% by dichotomized modified Rankin scale). Of the various scales used to measure disability in the NINDS study, the modified Rankin Scale is probably the most useful clinically, since it measures functional neurologic outcome. Patients were considered to be completely recovered from stroke if, 90 days after treatment, they scored less than 2 on the modified Rankin Scale (either no residual deficits or deficits without disability). The beneficial neurologic outcomes were sustained at 1 year and published in 1999.

NINDS also had a 6.4% rate of symptomatic intracranial hemorrhage in the rt-PA group that was higher than in the placebo group. In spite of this, an overall trend toward decreased mortality in the treatment group at 3 months (17% vs 21%) was noted. Subsequent number needed to treat (NNT) analysis of the NINDS stroke trial revealed that 1 of 8 patients given t-PA had complete neurologic recovery at 90 days, while 1 of 17 suffered symptomatic intracranial hemorrhage within the first 36 hours.

ECASS enrolled 620 patients in 75 hospitals in 14 European countries during the period 1992-1994. Eligible patients were those who presented within 6 hours of stroke symptom onset and had no hemorrhage by cranial CT scan. Excluded patients had severe hemispheric stroke symptoms (eg, hemiplegia with impaired level of consciousness or forced head or eye deviation) or improving symptoms, had recent trauma or surgery, were receiving anticoagulants, or had signs of early infarct on cranial CT scan, such as hypodensity or sulcal effacement in more than 33% of the MCA territory. Patients in the t-PA group were given 1.1 mg/kg of t-PA to 100 mg total over 1 hour (10% of the total dose was given over the first 1-2 min). Anticoagulation was not allowed for the first 24 hours after treatment.

Although ECASS, like the NINDS study, found an equivocally significant increase in full recovery by modified Rankin scale 90 days after treatment in the t-PA group (36% vs 29%), it also documented a statistically significant increase in mortality rate at 90 days (22% vs 16%). NNT analysis of the equivocal ECASS data revealed that 1 in 14 patients given t-PA had full neurologic recovery.

Proponents of t-PA have argued that the results of ECASS and NINDS cannot be compared directly because in ECASS a higher dose of t-PA was given (1.1 vs 0.9 mg/kg), t-PA was given during a longer window of time after symptom onset (6 vs 3 h), and patients may have received different supportive care in the participating centers (Europe vs US).

Further meta-analysis of studies thus far published revealed an overall rate of symptomatic hemorrhage to be 5.2%. However, studies evaluating protocol violations of the inclusion/exclusion criteria derived from the NINDS trial have had higher rates of symptomatic cerebral hemorrhage. Current AHA/ASA inclusion guidelines for the administration of rt-PA are as follows:

• Diagnosis of ischemic stroke causing measurable neurologic deficit

• Neurologic signs should not be clearing spontaneously

• Neurologic signs should not be minor and isolated

• Caution should be exercised in treating patients with major deficits

• Symptoms should not be suggestive of subarachnoid hemorrhage

• Onset of symptoms <3 hours before beginning treatment

• No head trauma or prior stroke in past 3 months

• No MI in prior 3 months

• No GI/GU hemorrhage in previous 21 days

• No arterial puncture in noncompressible site during prior 7 days

• No major surgery in prior 14 days

• No history of prior intracranial bleed

• SBP <185, DBP <110

• No evidence of acute trauma or bleeding

• Not taking an oral anticoagulant, or if so INR <1.7

• If taking Heparin within 48 hours must have a normal activated prothrombin time (apt)

• Platelet count >100,000

• Blood glucose level greater than 50 mg/dL (2.7 mmol)

• No seizure with residual postictal impairments

• CT does not show evidence of multilobar infarction (hypodensity >1/3 hem)

• The patient and family understand the potential risks and benefits of therapy

Streptokinase has not been shown to benefit patients with acute ischemic stroke, but it has been shown to increase their risk of intracranial hemorrhage and death. Of 3 major randomized controlled trials, all were terminated prematurely because streptokinase was associated with unacceptable rates of mortality.

The failure of streptokinase as a thrombolytic agent for acute ischemic stroke has been attributed to its long action and lack of clot specificity. While alteplase specifically activates plasminogen already bound to a thrombus, streptokinase activates unbound circulating plasminogen.

Intra-arterial thrombolysis

No human trials comparing the intravenous versus intra-arterial administration of thrombolytics exist. However, several authors have posited potential benefits from the intra-arterial approach. These advantages include the higher local concentrations of thrombolytic possibly allowing lower total doses (and theoretically less risk of systemic bleed) and a suggested longer therapeutic window, potentially out to 6 hours. Although this approach may show promise, further research is required. The time window for intra-arterial thrombolysis is 6 hours, but it may be extended up to 12 hours in unique circumstances.

Ultrasound-assisted thrombolysis

Given that a substantial proportion of patients treated with rt-PA have persistent disability and that one of the major reasons for this therapeutic failure is incomplete or slow thrombolysis, researchers have studied the use of transcranial ultrasound in assisting rt-PA in thrombolysis. In one study, patients were randomly assigned to either rt-PA with placebo or rt-PA along with continuous ultrasonography. A significant improvement occurred in the rate of recanalization, and a trend toward increased rate of stroke recovery was noted in the transcranial Doppler group. Further research is necessary to determine the exact role of transcranial Doppler ultrasonography in assisting thrombolytics in acute ischemic stroke.

Drug Name	Alteplase (Activase) -- Tissue plasminogen activator (t-PA) used in management of acute MI, acute ischemic stroke, and pulmonary embolism. Safety and efficacy with concomitant administration of heparin or aspirin during first 24 h after symptom onset have not been investigated.
Adult Dose	0.9 mg/kg IV over 60 min; not to exceed 90 mg; 10% of total dose administered as initial IV bolus over 1 min; administer only within 3 h of onset of stroke symptoms
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; concurrent aspirin or anticoagulant medication; acute intracranial hemorrhage on pretreatment evaluation; seizure at onset of stroke; history of intracranial hemorrhage; suspected subarachnoid hemorrhage; active internal bleeding; recent intracranial or intraspinal surgery or trauma; intracranial neoplasm; arteriovenous malformation or aneurysm; bleeding diathesis; severe uncontrolled hypertension
Interactions	Drugs that alter platelet function (aspirin, dipyridamole, abciximab) may increase risk of bleeding prior to, during, or after alteplase therapy; may give heparin with and after alteplase infusions to reduce risk of rethrombosis; either heparin or alteplase may cause bleeding complications
Pregnancy	D - Unsafe in pregnancy
Precautions	Monitor for bleeding, especially at arterial puncture sites or with coadministration of vitamin K antagonists; control and monitor BP frequently during and following alteplase administration (when managing acute ischemic stroke); do not use >0.9 mg/kg to manage acute ischemic stroke; doses >0.9 mg/kg may cause ICH

Drug Category: Anti-Platelet Agents -- Although antiplatelet agents have been shown useful for preventing recurrent stroke or stroke after TIAs, efficacy in the treatment of acute ischemic stroke has not been demonstrated. The International Stroke Trial and Chinese Acute Stroke Trial demonstrated modest benefit of aspirin in the setting of acute ischemic stroke. The International Stroke Trial randomized 20,000 patients within 24 hours of stroke onset to treatment with aspirin 325 mg, subcutaneous heparin in 2 different dose regimens, aspirin with heparin, and a placebo. The study found that aspirin therapy reduced the risk of early stroke recurrence. The Chinese Acute Stroke Trial evaluated 21,106 patients and had a 4-week mortality reduction of 3.3% contrasted to 3.9%. A separate study also found that the combination of aspirin and low molecular weight heparin did not significantly improve outcomes. Early aspirin therapy is recommended within 48 hours of the onset of symptoms but should be delayed for at least 24 hours after rt-PA
administration. Aspirin should not be considered as an alternative to intravenous thrombolysis or other therapies aimed at improving outcomes after stroke.

Other antiplatelet agents are also under evaluation for use in the acute presentation of ischemic stroke. In a preliminary pilot study, abciximab was given within 6 hours to establish a safety profile. A trend toward improved outcome at 3 months for the treatment versus the placebo group was noted. Further clinical trials are necessary.

Drug Name	Aspirin (Bayer Aspirin, Anacin, Bufferin) -- Blocks prostaglandin synthetase action, which, in turn, inhibits prostaglandin synthesis and prevents formation of platelet-aggregating thromboxane A2. Also acts on hypothalamic heat-regulating center to reduce fever.
Adult Dose	1.3 g/d PO divided bid/qid
Pediatric Dose	10-15 mg/kg/dose PO q4-6h; not to exceed 60-80 mg/kg/d
Contraindications	Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma Because of association with Reye syndrome, do not use in children ( <16 y) with flu
Interactions	Antacids and urinary alkalinizers may decrease effects; corticosteroids decrease serum levels; anticoagulants may cause additive hypoprothrombinemic effects and increased bleeding time; may antagonize uricosuric effects of probenecid and increase toxicity of phenytoin and valproic acid; doses > 2 g/d may potentiate glucose-lowering effect of sulfonylurea drugs
Pregnancy	D - Unsafe in pregnancy
Precautions	May cause transient decrease in renal function and aggravate chronic kidney disease; avoid use in severe anemia or coagulation defects, or in patients taking anticoagulants

Drug Name	Ticlopidine (Ticlid) -- Second-line antiplatelet therapy for patients who cannot tolerate aspirin or in whom aspirin not effective.
Adult Dose	250 mg PO bid
Pediatric Dose	Not established
Contraindications	Documented hypersensitivity; severe neutropenia or thrombocytopenia; liver damage; active bleeding disorders
Interactions	Corticosteroids and antacids decrease effects; theophylline, cimetidine, aspirin, and NSAIDs increase toxicity
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Discontinue if absolute neutrophil count decreases to <1200/mm3 or platelet count decreases to <80,000/mm3

FOLLOW-UP

Section 8 of 11

Further Inpatient Care:

• Referral to a physician with special interest in stroke is ideal. Stroke care units exist and are said to show improved outcomes with specially trained personnel. Comorbid medical problems need to be addressed. Serial monitoring and interventions when necessary early in the clinical course and eventual stroke rehabilitation are the ideals.

Patient Education:

• For excellent patient education resources, visit eMedicine's Stroke Center and Dementia Center. Also, see eMedicine's patient education articles Stroke, Transient Ischemic Attack (Mini-stroke), and Stroke-Related Dementia.

MISCELLANEOUS

Section 9 of 11

Medical/Legal Pitfalls:

• Informed consent

• If a treatment option is available, patients or their proxies should be allowed to decide whether to accept or reject it.

• Since t-PA can harm some patients, patients must understand clearly its risks and benefits and give their informed consent before t-PA is administered.

• Diagnostic recommendations

• The clinical diagnosis of stroke must be as accurate as possible, and special care must be taken to avoid the misdiagnosis of stroke mimics.

• Hospital protocols must be in place to ensure that patients with undifferentiated stroke have prioritized access CT imaging within 10 minutes of arrival.

• Therapeutic recommendations

• The benefit of early aspirin administration is modest.

• Systemic anticoagulation is not recommended.

• If the administration of t-PA is considered, care must be given to follow the current inclusion and exclusion criteria guidelines derived from the NINDS study. Protocol violations can result in higher rates of cerebral hemorrhage.

Special Concerns:

• With the advent of t-PA for use in selected patients with acute ischemic stroke, many medical professionals now consider undifferentiated stroke with symptom duration less than 3 hours to be a medical emergency.

• Specialized stroke care (stroke systems)

• Given the multitude of factors that comprise the care of the acute stroke patient, the concept of the specialized stroke center has evolved. Foremost amongst these factors is the issue of time. Given the current 3-hour window for the commencement of intravenous thrombolytics, efficient systems of triage must be in place to identify possible candidates of therapy.

• Furthermore, once patients have been identified as potential stroke victims, their emergency department evaluation must be fast-tracked to allow for the completion of required laboratory tests and requisite noncontrast head CT scanning as well as the notification and involvement of neurologic consultation. These requirements have led to the development of "stroke codes" or "stroke activations" in which EMS crews have been trained to identify possible stroke victims and arrange for their speedy transport to stroke centers. These specialized centers in turn have made the necessary arrangements to accelerate a standardized and organized process leading to potential thrombolysis.

• Additionally, stroke centers should have personnel versed at monitoring "stroke vital signs" such as blood pressure, glucose levels, temperature, oxygenation, and change in neurologic status. Cumulatively, the center should identify performance measures and include mechanisms for evaluating the effectiveness of the system as well as its component parts. The acute care of the stroke patient is more than anything a systems-based team approach requiring the cooperation of emergency department, radiology, pharmacy, neurology, and ICU staff.

• A stroke system should ensure effective interaction and collaboration among the agencies, services, and people involved in providing prevention and the timely identification, transport, treatment, and rehabilitation of individual stroke patients in a locality or region.

TEST QUESTIONS

Section 10 of 11

CME Question 1: Pharmacologic agents shown by randomized, controlled trials to benefit selected patients with acute ischemic stroke include which of the following?

A: Streptokinase, nitroprusside, and nimodipine
B: Tissue-plasminogen activator (t-PA), nitroprusside, and lubeluzole
C: t-PA, aspirin, and heparin
D: t-PA and heparin
E: t-PA alone

The correct answer is E: The National Institute of Neurologic Disorders and Stroke (NINDS) recombinant tissue-plasminogen activator (rt-PA) Stroke Trial is the only randomized, prospective, placebo-controlled trial in the entire stroke literature that shows a benefit for a therapeutic agent in the treatment of selected patients with acute ischemic stroke. Three studies have shown that streptokinase does not benefit patients. No studies adequately address the efficacy of antihypertensive agents, antithrombotic agents (aspirin, heparin), or neuroprotectants in the treatment of acute ischemic stroke.

CME Question 2: According to the National Institute of Neurologic Disorders and Stroke (NINDS) recombinant tissue-plasminogen activator (rt-PA) Stroke Trial, which of the following is not an exclusion criterion for administering tissue-plasminogen activator (t-PA)?

A: Hypoglycemia (glucose <50 mg/dL)
B: Symptoms suggestive of subarachnoid hemorrhage
C: A large hypodense region on head CT scan in more than 33% of the middle cerebral artery distribution
D: Previous stroke or head injury within the past 3 months
E: Stroke symptom onset more than 3 hours before the time t-PA is to be started

The correct answer is C: The presence of signs of early cerebral infarction on head CT scan was not one of the exclusion criteria in the NINDS study, although it should prompt a careful requestioning of the patient and witnesses about the exact time of onset of stroke symptoms. According to the NINDS study, t-PA must be started, although not necessarily completed, within 3 hours of stroke symptom onset. Great care must be taken to follow the exact inclusion and exclusion criteria set forth by the NINDS study when administering t-PA for acute ischemic stroke.

Pearl Question 1 (T/F): The key finding that distinguishes Bell palsy from stroke is the inability to close the eye on the affected side.

The correct answer is False: Inability to close the eye on the affected side may occur in either condition. Inability to elevate the eyebrows or wrinkle the forehead on the affected side is characteristic of Bell palsy alone and helps distinguishes it from stroke.

Pearl Question 2 (T/F): Sudden onset of weakness in one leg is characteristic of anterior cerebral artery stroke syndrome.

The correct answer is True: Anterior cerebral artery stroke syndromes preferentially affect the lower extremities. Middle cerebral artery stroke syndromes preferentially affect the face and upper extremities.

Pearl Question 3 (T/F): Sudden onset of hypesthesia over the right face and left body is characteristic of vertebrobasilar artery stroke syndrome.

The correct answer is True: Vertebrobasilar artery stroke syndromes cause loss of pain and temperature sensation in the ipsilateral face and contralateral body. Anterior stroke syndromes produce signs and symptoms on one side of the body only.

Pearl Question 4 (T/F): A patient with a new right gaze preference is most likely to have suffered an acute left middle cerebral artery stroke.

The correct answer is False: Right middle cerebral artery stroke causes the patient to look toward the right side. A left-sided seizure focus also causes a right gaze preference. Patients tend to look toward a deficit and away from a stimulus.

BIBLIOGRAPHY

Section 11 of 11

• AbESTT Investigators: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial. Stroke 2005 Apr; 36(4): 880-90[Medline].
• Adams H, Adams R, Del Zoppo G, et al: Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005 Apr; 36(4): 916-23[Medline].
• Adams HP, Adams RJ, Brott T, et al: Guidelines for the early management of patients with ischemic stroke: A scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003 Apr; 34(4): 1056-83[Medline].
• Adams HP Jr, Brott TG, Crowell RM, et al: Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1994 Sep; 25(9): 1901-14[Medline].
• Albers GW: Medical treatment for acute ischemic stroke. Am J Med 1996; 3-9.
• Albers GW, Clark WM, Madden KP, et al: ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. Stroke 2002 Feb; 33(2): 493-5[Medline].
• Alexandrov AV, Molina CA, Grotta JC, et al: Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004 Nov 18; 351(21): 2170-8[Medline].
• Barber PA, Zhang J, Demchuk AM, et al: Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001 Apr 24; 56(8): 1015-20[Medline].
• Barsan WG, Kothari R: Stroke. Emergency Medicine Concepts and Practices. Vol 3. 1998: 2184-98.
• Bronner LL, Kanter DS, Manson JE: Primary prevention of stroke. N Engl J Med 1995 Nov 23; 333(21): 1392-400[Medline].
• Brott T, Bogousslavsky J: Treatment of acute ischemic stroke. N Engl J Med 2000 Sep 7; 343(10): 710-22[Medline].
• Chan YF, Kwiatkowski TG, Rella JG, et al: Tissue plasminogen activator for acute ischemic stroke: a New York city emergency medicine perspective. J Emerg Med 2005 Nov; 29(4): 405-8[Medline].
• Christensen H, Fogh Christensen A, Boysen G: Abnormalities on ECG and telemetry predict stroke outcome at 3 months. J Neurol Sci 2005 Jul 15; 234(1-2): 99-103[Medline].
• Cocho D, Belvis R, Marti-Fabregas J, et al: Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology 2005 Feb 22; 64(4): 719-20[Medline].
• del Zoppo GJ, Higashida RT, Furlan AJ, et al: PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998 Jan; 29(1): 4-11[Medline].
• Fieschi C, Hacke W, Kaste M, et al: Thrombolytic therapy for acute ischaemic stroke. ECASS Study Group. Lancet 1997 Nov 15; 350(9089): 1476; author reply 1477[Medline].
• Furlan A, Higashida R, Wechsler L, et al: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 1999 Dec 1; 282(21): 2003-11[Medline].
• Gobin YP, Starkman S, Duckwiler GR, et al: MERCI 1: a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 2004 Dec; 35(12): 2848-54[Medline].
• Grotta J, Bratina P: Subjective experiences of 24 patients dramatically recovering from stroke. Stroke 1995 Jul; 26(7): 1285-8[Medline].
• Gubitz G, Sandercock P, Counsell C: Anticoagulants for acute ischaemic stroke. Cochrane Database Syst Rev 2004; CD000024[Medline].
• Hacke W, Kaste M, Fieschi C, et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998 Oct 17; 352(9136): 1245-51[Medline].
• Hacke W, Donnan G, Fieschi C, et al: Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004 Mar 6; 363(9411): 768-74[Medline].
• Hacke W, Kaste M, Fieschi C, et al: Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995 Oct 4; 274(13): 1017-25[Medline].
• Jones MM, Nogajski JH, Faulder K, et al: Intra-arterial thrombolysis in acute ischaemic stroke. Intern Med J 2005 May; 35(5): 300-2[Medline].
• Kase CS, Wolf PA, Chodosh EH, et al: Prevalence of silent stroke in patients presenting with initial stroke: the Framingham Study. Stroke 1989 Jul; 20(7): 850-2[Medline].
• Kasner SE, et al: Emergency identification and treatment of acute ischemic stroke. Ann Emerg Med 1997 Nov; 30(5): 642-53[Medline].
• Kwiatkowski TG, Libman RB, Frankel M, et al: Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med 1999 Jun 10; 340(23): 1781-7[Medline].
• Leira EC, Chang KC, Davis PH, et al: Can we predict early recurrence in acute stroke?. Cerebrovasc Dis 2004; 18(2): 139-44[Medline].
• Lewandowski C, Barsan W: Treatment of acute ischemic stroke. Ann Emerg Med 2001 Feb; 37(2): 202-16[Medline].
• Libman RB, et al: Conditions that mimic stroke in the emergency department. Implications for acute stroke trials. Arch Neurol 1995 Nov; 52(11): 1119-22[Medline].
• Lyden PD, et al: A critical appraisal of stroke evaluation and rating scales. Stroke 1991 Nov; 22(11): 1345-52[Medline].
• Macleod MR, Davis SM, Mitchell PJ, et al: Results of a multicentre, randomised controlled trial of intra-arterial urokinase in the treatment of acute posterior circulation ischaemic stroke. Cerebrovasc Dis 2005; 20(1): 12-7[Medline].
• National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 1995; 333: 1581-7[Medline].
• National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group: Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience. Ann Emerg Med 2005 Sep; 46(3): 243-52[Medline].
• National Stroke Association Consensus Group: Stroke: the first hours - emergency evaluation and treatment. Stroke Clin Updates 1997; 5-14.
• Noor R, Wang CX, Shuaib A: Hyperthermia masks the neuroprotective effects of tissue plaminogen activator. Stroke 2005 Mar; 36(3): 665-9[Medline].
• Parnetti L, Caso V, Santucci A, et al: Mild hyperhomocysteinemia is a risk-factor in all etiological subtypes of stroke. Neurol Sci 2004 Apr; 25(1): 13-7[Medline].
• Raco, et al: Management of acute cerebellar infarction: One institution's experience. Neurosurgery vol 53(5) Nov 2005: 1061-1065.
• Ribo M, Molina CA, Rovira A, et al: Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005 Mar; 36(3): 602-6[Medline].
• Savitz SI, Caplan LR: Vertebrobasilar disease. N Engl J Med 2005 Jun 23; 352(25): 2618-26[Medline].
• Schwamm LH, Pancioli A, Acker JE, et al: Recommendations for the establishment of stroke systems of care: recommendations from the American Stroke Association's Task Force on the Development of Stroke Systems. Circulation 2005 Mar 1; 111(8): 1078-91[Medline].
• Smith WS, Sung G, Starkman S, et al: Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005 Jul; 36(7): 1432-8[Medline].
• The Multicenter Acute Stroke Trial-Europe Study Group: Thrombolytic therapy with streptokinase in acute ischemic stroke. The Multicenter Acute Stroke Trial--Europe Study Group. N Engl J Med 1996 Jul 18; 335(3): 145-50[Medline].
• The NINDS rt-PA Stroke Study Group: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995 Dec 14; 333(24): 1581-7[Medline].
• Tomson J, Lip GY: Blood pressure changes in acute haemorrhagic stroke. Blood Press Monit 2005 Aug; 10(4): 197-9[Medline].
• Wechsler LR, Roberts R, Furlan AJ, et al: Factors influencing outcome and treatment effect in PROACT II. Stroke 2003 May; 34(5): 1224-9[Medline].
• Wilterdink JL, Bendixen B, Adams HP, et al: Effect of prior aspirin use on stroke severity in the trial of Org 10172 in acute stroke treatment (TOAST). Stroke 2001 Dec 1; 32(12): 2836-40[Medline].
• Wyer PC, Osborn HH: Recombinant tissue plasminogen activator: in my community hospital ED, will early administration of rt-PA to patients with the initial diagnosis of acute ischemic stroke reduce mortality and disability?. Ann Emerg Med 1997 Nov; 30(5): 629-38[Medline].
• Yundt KD, Diringer MN: The use of hyperventilation and its impact on cerebral ischemia in the treatment of traumatic brain injury. Crit Care Clin 1997 Jan; 13(1): 163-84[Medline].
• Zweifler RM: Management of acute stroke. South Med J 2003 Apr; 96(4): 380-5[Medline].

eMedicine Journals > Emergency Medicine > Neurology > Stroke, Ischemic

Please email us with any comments you have on our new chapter format.

Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Bibliography